Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17012038 | 0.80 | CYP1A2 (0.46) | MAOBPIN1CYP1A2TSHRALDH1A1 | |
| SCHEMBL17010218 | 0.80 | MAOB (0.55) | MAOBMAPK14PIN1CYP1A2TSHR | |
| SCHEMBL24844977 | 0.80 | APP (0.50) | MAOBMAPK14PIN1CYP1A2TSHR | |
| SCHEMBL2779108 | 0.79 | LTA4H (0.55) | MAOBMAPK14CYP1A2TSHRCYP2C19 | |
| SCHEMBL20657592 | 0.78 | APP (0.50) | MAOBTSHRRAB9ASMN1; SMN2 | |
| SCHEMBL17129498 | 0.78 | NPC1 (0.59) | MAOBALDH1A1LMNAL3MBTL1MAOA | |
| SCHEMBL1547807 | 0.78 | ACACB (0.55) | MAOBGABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3109590 | 0.77 | MAPT (0.41) | CYP1A2TSHRALDH1A1CLK4CYP2C19 | |
| SCHEMBL510168 | 0.77 | GABRA5 (0.52) | MAOBGABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29457401 | 0.77 | GABRA5 (0.52) | MAOBGABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024125603-A1 | SHP2 INHIBITOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-118206550-A | SHP2 inhibitor and application thereof | 江苏威凯尔医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-113549069-A | Kinase inhibitor | 重庆复创医药研究有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-108779117-B | Kinase inhibitor | 重庆复创医药研究有限公司 | 2021-08-31 | — | — | CN | disclosed |
| WO-2021149767-A1 | HETEROCYCLIC DERIVATIVE | 大日本住友製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
| CN-107667107-B | Ethynyl derivatives | 豪夫迈·罗氏有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3331882-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| CN-108779117-A | Kinase inhibitor | 重庆复创医药研究有限公司 | 2018-11-09 | — | — | CN | disclosed |
| US-10011607-B2 | Ethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| CN-101466679-A | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-06-24 | — | — | CN | disclosed |
| EP-2007728-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
| US-20060247260-A1 | Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | US | disclosed |
| EP-1594846-A1 | BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069805-A1 | BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011607-B2 | Ethynyl derivatives | CCRL2, MC2R, CCR2 | MAOB 191/4885MAPK14 2914/4885PIN1 1415/4885 |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | PCSK9, LSS, DHCR7 | MAOB 1678/4885MAPK14 839/4885PIN1 4553/4885 |
| US-20060247260-A1 | Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists | HRH2, BPHL, HRH1 | MAOB 2096/4885MAPK14 3212/4885PIN1 1243/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | MAOB 4698/4885MAPK14 1767/4885PIN1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.